Evaluating Clinical Effects of a Spray-Type Bio-absorbable Adhesion Barrier System in Paediatric Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-01

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective randomized single-blind study where a placebo group served the control, to confirm the efficacy and safety of AdSpray™ as an inhibitory effect of postoperative adhesion formation in paediatric patients who underwent laparotomy with stoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Bioresorbable Sheet to Prevent Intra-Abdominal Adhesions in Colorectal Surgeries

NCT00902148

Adhesions

COMPLETED PHASE4

Evaluation of the Safety and Effectiveness of Sepraspray™ in Reducing Post-surgical Adhesions

NCT00665730

Abdominal Adhesions

TERMINATED NA

Efficacy and Safety Study of Anti-Adhesion Product in the Prevention of Intraperitoneal Adhesions

NCT00512356

Intraperitoneal Adhesions

COMPLETED PHASE2

An Adhesion Reduction Plan in the Management of the Surgical Open Abdomen

NCT01010464

Open Abdomen

WITHDRAWN NA

Transversus Abdominis Plane Block in Children Undergoing Ostomy Surgery

NCT01136668

Anesthesia Ostomy

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Postoperative adhesions are fibrovascular bands connecting the parietal peritoneum to the visceral peritoneum of intra-abdominal organs, or connecting intra-abdominal organs to one another, which developed unavoidably following virtually all body cavity surgeries. Adhesions affect up to 80-93% of patients following abdominal surgery. Being the leading cause of postoperative small bowel obstruction, it could potentially cause other enormous clinical problems including difficulty in subsequent operations, infertility, and chronic pain. The incidence of adhesion-related morbidity is estimated to be 2.2% to 19.5% in the pediatric population, among which large proportion of patients required subsequent surgical intervention. A variety of techniques and products (e.g. bioresorbable physical barrier agents, pharmacological adjuncts, etc) have been advocated for preventing postoperative adhesion formation. However, to date, no single treatment is proven to be effective and adhesions still remain a significant, unresolved postoperative complication both in adults and paediatric populations.

To reduce postoperative adhesions, Terumo Corporation (Tokyo, Japan) has developed an adhesion barrier system (AdSpray™; Terumo Corporation, Tokyo, Japan) which is easy to use at the treatment site in various surgical procedures. Its ability of adhesion prevention had been demonstrated in porcine model study. Cezar et al and Suto et al subsequently published two human prospective randomized controlled trials on the use of this barrier system in adult patients undergoing gynaecological and gastrointestinal operations, which confirmed its safety and efficacy. However, to date, studies on the use of anti-adhesion agents in children are scarce and there is no study on this novel barrier system (AdSpray™) in children. In view of this, we plan to conduct a prospective randomized single-blind study where a placebo group served the control, to confirm the efficacy and safety of AdSpray™ as an inhibitory effect of postoperative adhesion formation in paediatric patients who underwent laparotomy with stoma.

B. Study objective To investigate the effect of a novel spray-type, novel dextrin hydrogel adhesion barrier (AdSpray™; Terumo Corporation, Tokyo, Japan) on postsurgical adhesions.

C. Study design and methods This is a prospective, single center, single-blinded randomized controlled trial using a parallel arm design and placebo group as the control. Patient enrollment will start in March 2022 and expected to end in 2023.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Surgical Adhesions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Eligible subjects will be identified, and parents will be approached for patient recruitment. Once consent to participation is signed, the patients will be randomised into either treatment group (AdSpray™) or placebo-controlled group in 1:1 ratio using simple randomization. The adhesion-assessment team will be blinded to the group allocated. The spray will be prepared according to the group allocated by a dedicated scrub nurse. For treatment group, AdSpray™ will be instilled into the drug chamber; for placebo group, saline will be instilled instead.

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

After completion of necessary operative procedures in the primary operation, barrier agent (AdSpray™or Placebo) will be sprayed to fully cover the organs under the laparotomy incision. At the second-look surgery, laparoscopic video recordings of the area under the laparotomy incision will be made in both groups. For the efficacy evaluation, based on the laparoscopic images of the abdominal cavity at the time of the second-look surgery, the presence, extent, and severity of adhesions will be assessed by the adhesion-assessment team which is independent of the study. The independent adhesion-assessment team will assess the extent and severity of adhesions under the laparotomy incision on a 4-grade scale.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Arm

Application of AdSpray™ over all organs under the laparotomy incision at the end of operation

Group Type EXPERIMENTAL

Adspray

Intervention Type DEVICE

Application of AdSpray™ over all organs under the laparotomy incision at the end of operation

Control Arm

Spray with saline would be applied to organs under incision

Group Type PLACEBO_COMPARATOR

Placebo-control

Intervention Type PROCEDURE

Spray with saline would be applied to organs under incision

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adspray

Application of AdSpray™ over all organs under the laparotomy incision at the end of operation

Intervention Type DEVICE

Placebo-control

Spray with saline would be applied to organs under incision

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients requiring laparotomy and staged operation with closure of stoma as second operation e.g. Necrotising Enterocolitis, Anorectal malformation, Hirschsprung's disease, etc.

Exclusion Criteria

* A history of hypersensitivity to substances derived from corn starch
* A history of surgery in the abdominal cavity or pelvic cavity accompanied by a laparotomy scar
* Patients with peritonitis
* Laparoscopic assessment of adhesions may not be performed safely at the second-look surgery.

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No